Transcatheter tricuspid and mitral devices Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines transcatheter therapies for the mitral and tricuspid valves, meaning devices delivered through a vein or a small puncture that repair or replace a leaking valve without open heart surgery. It tests how far these therapies can grow from a small group of patients who cannot have surgery to a broader structural heart population by 2035.

Approvals widened the toolkit in late 2025 and 2026. Edwards announced FDA approval of Sapien M3 on 23 December 2025, the first transseptal transcatheter therapy approved for mitral regurgitation, for patients unsuitable for surgery or edge-to-edge repair, on the basis of a 299 patient pivotal trial, and on 21 October 2026 it announced FDA approval of Pascal for transcatheter edge-to-edge repair of the tricuspid valve. The conclusion is that mitral replacement and tricuspid repair now have more than one approved option, which opens competition and lowers the barrier for hospitals to start programmes.

The market is moving to a repair and replacement choice. Abbott already has an approved tricuspid repair device in TriClip and an approved mitral replacement device in Tendyne from May 2025, while Edwards states that it is the only company in the United States offering both repair and replacement transcatheter therapies for the mitral and tricuspid valves. The conclusion is that patient anatomy, rather than a single device, will decide treatment, and portfolio breadth gives an advantage.

Coverage and care models are being set. The Centers for Medicare and Medicaid Services finalised a national coverage determination for tricuspid edge-to-edge repair with any FDA-approved device when a full heart team with tricuspid experience is involved, and a 2026 expert consensus document from the main United States cardiology societies sets operator and institutional requirements for tricuspid interventions. The conclusion is that coverage rules favour centres with trained teams, which shapes who can offer the therapy.

The brief treats transcatheter mitral and tricuspid therapies as an accelerating signal with a nine year horizon to 2035. It identifies which devices and companies move first and what each means for device makers, hospitals and heart teams. It is a focused 110-page decision brief that presents an indicative trajectory rather than a segmented market model.

The mitral valve controls blood flow from the left upper chamber to the left lower chamber and the tricuspid valve does the same on the right side of the heart. When either leaks, the heart works harder and symptoms of heart failure follow. Surgery has been the standard treatment, but many patients are too frail for it, so catheter-based repair and replacement have grown.

Edge-to-edge repair clips the valve leaflets together and is the more established route. Edwards states that Pascal is now approved for tricuspid repair in patients who remain symptomatic despite medical therapy, have at least intermediate surgical risk and are good candidates in the view of a multidisciplinary heart team, and that one year outcomes from the CLASP II TR trial are to be presented at TCT 2026. The conclusion is that the tricuspid repair market moves from a single approved device to two, and data from CLASP II TR will guide uptake.

Replacement is the second route and is aimed at patients whom repair cannot help. Sapien M3 delivers a dock first and then a valve across the septum, and Edwards described it as the first approved transseptal therapy for mitral regurgitation, with a CE mark earlier in 2025. Edwards Evoque is already approved for tricuspid replacement, while Abbott does not offer transcatheter tricuspid replacement. The conclusion is that replacement extends the treatable population, and Edwards has the widest approved range in the tricuspid and mitral space.

Care models matter as much as devices. A Medicare national coverage determination requires a heart team of a cardiac surgeon, an interventional cardiologist, a heart failure specialist and an interventional echocardiographer, each experienced in tricuspid disease. The conclusion is that growth depends on the number of centres with such teams, and programmes that build teams early gain volume first.

The limits are anatomy and patient selection, training and centre capacity, the limited trial evidence for newer indications and long-term durability. The brief tests each limit against the cost trajectory to 2035.

The transcatheter mitral and tricuspid therapies market, covering transcatheter edge-to-edge repair devices, transcatheter mitral and tricuspid valve replacement systems and associated repair implants, and excluding transcatheter aortic valve systems, surgical valves and repair rings, imaging systems and heart failure drugs, is valued at USD 2.0–3.0 billion in 2026 and is projected to reach USD 8.87–13.31 billion by 2035, at a CAGR of 18%.

The 2026 base rests on mitral and tricuspid repair and replacement devices sold mainly in the United States, Europe and Japan. Growth then follows coverage, the number of centres with trained heart teams and the spread of replacement devices.

The forecast is sensitive to coverage decisions outside the United States, the results of pivotal and registry trials and the pace of centre training.

Scenarios.

The base case assumes coverage stays in place and centres add heart teams steadily, bringing the inflection to about 2029 and a 2035 value near the middle of the range. An accelerated case assumes strong CLASP II TR and Sapien M3 data and coverage outside the United States, bringing the inflection to 2027 and lifting the 2035 value to the top of the range. A delayed case assumes slow centre training and mixed durability data, moving the inflection to 2032 and holding growth at the bottom of the range.

Growth drivers

• Valve disease prevalence.
• Patients unsuitable for surgery.
• Outcomes against medical therapy.
• New tricuspid and mitral indications.

Enablers

• Imaging and procedure planning.
• Less invasive delivery systems.
• Reimbursement and registry evidence.
• Heart team programmes.

Restraints and barriers

• Anatomy and patient selection limits.
• Training and centre capacity.
• Limited trial evidence for newer indications.
• Skills.

The direction of transcatheter mitral and tricuspid therapy is set by regulatory approvals, Medicare coverage, the size of the untreated valve disease population, imaging and delivery advances and the capacity of heart teams.

The key participants in transcatheter mitral and tricuspid therapies include Edwards Lifesciences Corporation, Abbott Laboratories, Medtronic plc, Innovalve Bio Medical Ltd., VDyne, Inc., Trisol Medical Ltd., TRiCares SAS, 4C Medical Technologies, Inc., Cardiovalve Ltd., NeoChord, Inc., Jenscare Scientific Co., Ltd., Peijia Medical Limited, Venus Medtech (Hangzhou) Inc., MicroPort CardioFlow Medical Technology Limited, HighLife SAS, CardioMech AS, Anteris Technologies Global Corp., Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Boston Scientific Corporation, Terumo Corporation, Integer Holdings Corporation, Cirtec Medical Corp., Artivion, Inc., HCA Healthcare, Inc., Mayo Clinic, Cleveland Clinic, Kaiser Foundation Health Plan, Inc., Novartis AG, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, the American College of Cardiology, the American Heart Association, the American Society of Echocardiography, the Society of Thoracic Surgeons, the Cardiovascular Research Foundation and the Centers for Medicare & Medicaid Services.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as replacement joins repair.

Edwards, Abbott and Medtronic lead among established structural heart makers, Innovalve, VDyne, Trisol, TRiCares and 4C Medical among mitral and tricuspid specialists, and Siemens Healthineers, GE HealthCare and Philips among imaging companies. Competitive intensity is moderate, with two large makers in the United States and a long list of specialists in trials.

Where value migrates.

In 2026 value sits with edge-to-edge repair, because it is covered and trained teams already exist at many centres. By 2029 it moves toward replacement devices and the makers that can offer both repair and replacement as heart teams spread. By 2035 it settles with transcatheter therapy as a standard option, where portfolio breadth, long-term data and training carry the margin. Margins hold for makers with full portfolios and registries, and narrow for makers of single devices in narrow anatomies.

The signals converge on a market where approvals and coverage are in place and capacity is the next limit. FDA approvals for mitral replacement and a second tricuspid repair device and Medicare coverage support growth, while anatomy, centre training and limited trial evidence in newer indications hold back adoption.

Structural limits show where progress could slow: the number of centres with heart teams, patient selection, long-term durability and coverage outside the United States. The brief therefore tracks four indicators: procedures per year, centres with tricuspid and mitral programmes, new approvals and long-term outcome data.

Repair first, then replacement and wider indications, then standard option status is the expected order of change.